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Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new step-
wise diagnostic process, the ‘HFA–PEFF diagnostic algorithm’. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory set-
ting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly,
atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of
breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac
ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of
HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically
performed by a cardiologist. Measures include mitral annular early diastolic velocity (e0), left ventricular (LV) filling pressure estimated
using E/e0, left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic
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strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score >_5
points implies definite HFpEF; <_1 point makes HFpEF unlikely. An intermediate score (2–4 points) implies diagnostic uncertainty, in which
case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2:
Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for
a better classification of HFpEF.
...................................................................................................................................................................................................
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Introduction
In the general population aged >_60 years, 4.9% were identified to
have heart failure with preserved ejection fraction (HFpEF),1 imply-
ing several millions of affected individuals in Europe. This number
is expected to increase further as people live longer and obesity
and diabetes become more common.1–3 Heart failure with pre-
served ejection fraction already accounts for more than half of all
heart failure (HF) hospital admissions.1 Providing effective manage-
ment is a major unmet clinical need that will depend on a clear
diagnosis.
The Heart Failure Association (HFA) of the European Society
of Cardiology (ESC) published a consensus statement in 2007
on ‘How to diagnose diastolic heart failure’.4 Since then, termin-
ology has evolved through HF with normal ejection fraction
(HFnEF) to the current definition as ‘HF with preserved ejec-
tion fraction’.4
Additional diagnostic criteria for HFpEF have been published,
including one scoring system,5 but they differ in echocardiographic
cut-off values, the role of comorbidities, the inclusion of biomarkers,
the role of invasive haemodynamic assessment, and the role of exer-
cise stress testing.3,4,6–8 Understanding of the pathophysiology of
HFpEF has advanced,9–13 diagnostic options have evolved,14–17 and
this novel information needs to be integrated into a new comprehen-
sive diagnostic algorithm for suspected HFpEF.
A writing committee initiated by the HFA of the ESC has
therefore produced an updated consensus recommendation—
the HFA–PEFF diagnostic algorithm (Figure 1). Its key elements
are (i) the concept that identification of HFpEF involves all lev-
els of care, including general practitioners, internists, general
cardiologists, HF specialists, and invasive cardiologists; (ii) a
stepwise diagnostic approach from initial clinical assessment to
more specialized tests will therefore be useful; (iii) the diagnosis
is not always straightforward, so the integration of distinct
parameters from complementary diagnostic domains into a new
diagnostic score is recommended; (iv) for the subset of patients
with an inconclusive score, definitive diagnosis (or exclusion)
will require invasive haemodynamics and/or non-invasive or in-
vasive exercise stress tests; and (v) underlying pathophysiologic-
al alterations (such as chronotropic incompetence, reduced LV
compliance) and specific aetiologies (such as amyloidosis18)
have to be considered. A precise diagnosis is increasingly im-
portant since new targeted therapies are becoming available for
defined subsets of HFpEF patients.
Why new diagnostic
recommendations for heart
failure with preserved ejection
fraction?
The key criteria in the previous HFA recommendations were: (i)
symptoms and/or signs of HF, (ii) normal or only mildly abnormal LV
systolic function, and (iii) LV diastolic dysfunction.4 Diagnostic param-
eters were invasive measurements, echocardiographic indices of LV
diastolic function and filling pressures, LV hypertrophy (LVH), left
atrial (LA) enlargement, serum natriuretic peptides (NP), and atrial
fibrillation (AF).4 Over time, both advantages and disadvantages of
this approach have been reported.
Cut-offs for key non-invasive parameters are often based on lim-
ited data, and may fall in a non-diagnostic intermediate range. The
non-invasive diagnosis or exclusion of HFpEF will not depend on a
single parameter above or below a certain cut-off, but on a combin-
ation of parameters derived from clinical, laboratory, and imaging
tests that together will give a probability for the diagnosis. A recent
example of such an approach was a composite HFpEF diagnostic
score, derived retrospectively from clinical characteristics (age
>60 years, obesity, atrial fibrillation, treatment with >_2 antihyperten-
sive drugs) and echocardiographic measurements [E/e0 >9, pulmon-
ary artery systolic pressure (PASP) >35 mmHg].5
Echocardiographic criteria for diagnosing
heart failure with preserved ejection
fraction
Left ventricular ejection fraction (LVEF) estimates global function but
does not indicate LV volume or stroke volume. Despite a preserved
LVEF, patients with HFpEF have impaired LV long-axis systolic func-
tion, which can be measured using mitral annular systolic excursion
or systolic velocities or LV global longitudinal strain (GLS).19 As well
as global diastolic dysfunction, they have long-axis diastolic dysfunc-
tion which can be measured from the velocity of long-axis lengthen-
ing of the LV in early diastole (from mitral annular velocity, e0). These
were not considered in the previous HFA recommendations.4
A mean E/e0 index >_15 at rest has good diagnostic value for identi-
fying a high mean pulmonary capillary wedge pressure (mPCWP),
supporting the likelihood of HFpEF,20,21 but an E/e0 ratio within the
intermediate range (9–14) is less sensitive.22 The E/e0 ratio has limita-
tions that are relevant in routine clinical practice23–29 and its use as a






























































..single diagnostic index above all other non-invasive measures of filling
pressures (such as retrograde pulmonary venous flow) cannot be
recommended. In consequence, HFpEF cannot be diagnosed from a
single echocardiographic measure, and inclusion of recently validated
functional and structural parameters into a diagnostic score may bet-
ter define this heterogeneous disorder.
Usefulness of natriuretic peptides
In general, NP levels are higher in patients presenting with acute
shortness of breath for cardiac reason or in acute HF, than in
patients who have chronic HF.30,31 Of note, our recommendations
target stable symptomatic HFpEF, and natriuretic peptide levels
can be normal in these patients even with invasively confirmed
HFpEF. In consequence, normal NP levels do not exclude HFpEF,
especially in the presence of obesity.32,33 Interpretation depends
also on whether the patient is in sinus rhythm (SR) or has AF,
which itself is associated with increased NP levels even in the ab-
sence of HF.34,35
Besides obesity, sex, age, and renal function affect NP levels,36,37
but using stratified cut-points only marginally improves diagnostic ac-
curacy (net reclassification index 3%),38 at the expense of less every-
day utility. The variability of repeated measurements in individual
patients is up to 100%, so a rise or fall of <_100% may not necessarily
indicate recovery or progression of disease.39,40
Diagnostic algorithms for heart failure
with preserved ejection fraction
The concept of a diagnostic algorithm that incorporates imaging and
biomarkers (NPs) was recommended by the HFA in 2007,4 and
adapted by others.41 It allowed parallel diagnostic pathways starting
from haemodynamic measurements, echocardiography, or NPs,4
that could yield different results for the same patients. In addition, the
proportion of non-classifiable patients was substantial. Thus, our
revised algorithm (see below) proposes a novel stepwise diagnostic




Heart failure with preserved ejection fraction typically evolves from a
combination of risk factors and comorbidities, including advanced
age, female sex, obesity, systemic arterial hypertension, diabetes mel-
litus, renal dysfunction, anaemia, iron deficiency, sleep disorders, and
chronic obstructive pulmonary disease.1,2,11,42–44 Heart failure with
preserved ejection fraction ‘masqueraders’ such as heart valve dis-
ease, arrhythmias, and pericardial constriction need to be excluded.
Similarly, a patient with a normal LVEF and HF-like symptoms caused
by significant coronary artery disease (CAD) is also not considered
to have HFpEF.
Similar to current practice for heart failure with reduced ejection
fraction (HFrEF), we recommend applying the descriptive term
HFpEF for both the classical form with typical risk factors and comor-
bidities, and for rarer cases with a specific aetiology, provided that the
key diagnostic criteria are met. Specific aetiologies that may be treat-
able include inherited or acquired infiltrative, restrictive, inflamma-
tory, or genetic cardiomyopathies45–48 (Table 2). They should always
be considered once a diagnosis of HFpEF has been made (Table 2,
Supplementary material online, S2–S4). It has been suggested that
patients with HFrEF share a common mechanism that responds to
common treatment (inhibition of the renin-angiotensin system)3 but
there are other treatments for subsets of patients with HFrEF that
are specific (such as treating ischaemia when there is hibernating myo-
cardium, using targeted antiviral therapy or immune modulation in in-
flammatory HFrEF, and corticosteroid therapy in sarcoidosis-related
HFrEF); in that respect, our proposed use of the generic term HFpEF
is similar and should include specific myocardial aetiologies.
Basic mechanisms affecting the myocardium in HFpEF include
myocyte hypertrophy, systolic and diastolic dysfunction, energetic
abnormalities, interstitial fibrosis, inflammation, increased oxidative
stress, endothelial dysfunction, and impaired density and autoregula-
tion of the microcirculation.9,10,12,45–48,154,155 Cardiovascular patho-
physiological processes include increased systemic vascular
Figure 1 HFA-PEFF diagnostic algorithm. Overview of the diagnostic heart failure with preserved ejection fraction steps 1–4 (P–F). CT, computed
tomography; PET, positron emission tomography.



















resistance, increased conduit arterial stiffness, abnormal ventricular-
arterial coupling, reduced LV long-axis systolic function, slowed early
diastolic relaxation, reduced LV compliance with increased end-
diastolic stiffness, reduced LA reservoir and contractile function,
impaired right ventricular (RV) function, and chronotropic incompe-
tence.52,156–164 Patients often have reduced reserve of stroke vol-
ume, heart rate, and cardiac output (CO), and the increase in CO
relative to oxygen consumption is blunted.165 Heart failure with pre-
served ejection fraction patients typically have high LV filling pres-
sures, whether at rest and/or on exercise, and they may develop fluid
retention and an expanded plasma volume.28,159,164,166,167 All these
mechanisms might be targets for treatment.
In a meta-analysis, exercise capacity in HFpEF was related to chro-
notropic incompetence, high mPCWP, blunted augmentation of ar-
teriovenous oxygen-content difference (implying inadequate
perfusion of exercising skeletal muscles), reduced stroke volume re-
serve, and pulmonary hypertension.168 Changes in pulmonary artery
pressure (PAP) on exercise are determined by the interplay between
CO, PA compliance, pulmonary vascular resistance, and mPCWP.
The increase in PAP is flow-dependent so it is best reported in rela-
tion to the increase in CO; the upper limit of normal is þ3 mmHg/L/
min.169 There are haemodynamic differences between patients with
pre- and post-capillary pulmonary hypertension.164
We recommend that the pathophysiological phenotype(s) prevail-
ing in an individual HFpEF patient are determined, as that may allow
the selection of specific therapies (see diagnostic Step 4 below).
The new Heart Failure
Association diagnostic
recommendations
The flowchart (Figure 2) provides an overview of the new diagnostic
algorithm.
Step 1(P): Pre-test assessment
Step 1(P) should be performed in any patient who presents with
symptoms and/or signs compatible with a diagnosis of HF. It requires
a detailed clinical and demographic history; an electrocardiogram
(ECG); blood tests; standard echocardiography to exclude other
causes such as HFrEF or heart valve disease; and investigations for is-
chaemia, arrhythmias, anaemia, or pulmonary disease (Figure 2). NP
levels can be obtained if the assay is available; elevated levels suggest
heart disease but normal levels do not exclude HFpEF. Step 1(P) mir-
rors the 2016 ESC HF guidelines concerning initial HF diagnostic
workup.3
Symptoms and signs
Breathlessness on exertion (New York Heart Association Class II or
III) is highly sensitive for a diagnosis of HF but only moderately specific
(about 50%) for a cardiac cause.170 Orthopnoea is quite specific but
relatively insensitive. Patients with HFpEF often report reduced exer-
cise capacity and fatigue, out of proportion to cardiac abnormalities
at rest. In elderly, overweight and deconditioned persons, poor exer-
cise capacity, dyspnoea on exertion, and peripheral oedema may also
have a non-cardiac origin.
Electrocardiographic abnormalities
Patients may have electrocardiographic features of LVH (such as a
Sokolov-Lyon Index >_3.5 mV; abnormal repolarisation) and/or LA
enlargement, but there are no pathognomonic signs and the diagnos-
tic value of an ECG to identify HFpEF is poor.5 The most important
indication is to detect atrial fibrillation (AF), which is highly predictive
of underlying HFpEF.5,148
Figure 2 Flowchart of the HFA-PEFF diagnostic algorithm. Step P
is meant to identify patients with the potential diagnosis of heart fail-
ure with preserved ejection fraction, and exclude or identify other
specific causes for their heart failure-like symptoms. Patients likely
to have heart failure with preserved ejection fraction are those with
typical demographics (e.g. elderly, female, and comorbidities), a pre-
served left ventricular ejection fraction on a standard echocardiog-
raphy, and other easily detectable findings such as elevated
natriuretic peptides or atrial fibrillation. Alternative causes such as
coronary artery disease, significant valvular disease, pulmonary dis-
ease, and anaemia should be excluded during this initial workup. If
Step P is positive, the second Step E should be done, which includes
a comprehensive echocardiography and brain natriuretic peptide/
N-terminal natriuretic peptide levels, if not already done on Step P.
Step F1 should be done, if Step E is inconclusive. Depended on clin-
ical facilities and patient conditions an invasive or non-invasive stress
test is recommended. However, the invasive stress test has a higher
validity and is an option, if the result of the non-invasive stress test is
not conclusive. The fourth Step, Step F2 is designed to identify a spe-
cific aetiology, if appropriate, when heart failure with preserved
ejection fraction has been diagnosed. For details of steps 2–4, see
Figures 3–5.






































































Several tests are recommended, including: sodium, potassium, urea,
and creatinine (with an estimated glomerular filtration rate); liver
function tests; HbA1c (metabolic syndrome and type 2 diabetes are
common comorbidities); thyroid stimulating hormone; and full
blood count, ferritin, transferrin saturation, and for anaemia. Anaemia
associated with HFpEF aggravates symptoms and exercise
intolerance.171,172
Natriuretic peptides
Multiple studies in primary care have shown that serum levels
<125 pg/mL (or ng/L) for N-terminal pro-brain natriuretic peptide
(NT-proBNP) or <35 pg/mL for BNP, have high negative predictive
values (NPV; 95–99%) for excluding any heart failure.39,40,121,173–177
The main trigger for release of NPs is high LV end-diastolic wall
stress, which is inversely proportional to wall thickness. It is therefore
understandable that the excellent NPV of NPs is true particularly for
HFrEF with a dilated LV, but not necessarily for HFpEF where LVH
tends to normalize wall stress. In consequence, it has become clear
that up to 20% of patients with invasively proven HFpEF have NPs
below these diagnostic thresholds,28,178–180 which represents a limi-
tation to the use of NPs. Therefore, it is important to understand
that with our SCORE approach HFpEF can still be diagnosed even, if
NP cut-offs (stratified by SR vs. AF) are below the given thresh-
olds’.28,178–180
Echocardiography
Standard echocardiography should be performed in every breathless
patient in whom there is clinical suspicion of HF, unless all the factors
listed in Table 1 are absent or negative. Echocardiography may ex-
clude alternative causes of dyspnoea such as HFrEF, valve disease, pri-
mary pulmonary hypertension, or pericardial effusion.181,182
Left ventricular ejection fraction should be measured, not esti-
mated, ideally from biplane or three-dimensional images. Only small
variations in normal ranges for EF by age, gender, and ethnic group
have been reported, so it is recommended that a single cut-point of
>_50% is applied to define a ‘preserved’ EF. Left ventricular diameters
and volumes should also be recorded. A diagnosis of HFpEF is sug-
gested if there is a non-dilated LV with a normal EF, concentric
remodelling or LVH, and left atrial enlargement. Echocardiographic
findings at rest compatible with this HFpEF phenotype are often
found in asymptomatic patients, who are at risk of progressing to
overt HFpEF.183,184 Of note, the presence of structural alterations on
echocardiography supports, but its absence does not exclude HFpEF.
A more detailed or advanced echocardiographic study (see Step
2(E); Supplementary material online, S1) is not necessary at this step,
but if it can be performed then only one examination will be needed.
Exercise tests
Coexisting epicardial stenotic coronary artery disease in patients
with HFpEF impacts on mortality and should be detected and
treated.133 Coronary microvascular dysfunction is part of the HFpEF
pathophysiology134 so non-invasive stress testing can give false-
positive results.134,186 Nonetheless, a bicycle or treadmill exercise
test, or tests with higher sensitivity to detect ischaemia such as
dobutamine stress echocardiography, cardiac magnetic resonance
(CMR) imaging, or myocardial scintigraphy, or an anatomical ap-
proach using coronary computed tomography (CT) angiography or
invasive angiography, should be considered if CAD is suspected.187
A stress test provides information about exercise capacity, the
blood pressure response to exercise (which may be hypertensive),
and the heart rate response. Chronotropic incompetence is present
in 33–77% of HFpEF patients,188,189 and defined as the failure to reach
70–80%188–190 of the predicted maximal heart rate. Reduced heart
rate recovery after exercise has prognostic value.191–193 Reduced ex-
ercise capacity can be defined as a peak workload <_75% of the value
predicted for age. In elderly patients with suspected HFpEF a 6-
minute walk test (6MWT) distance <_300 m can be considered abnor-
mal193 but 6MWT performance is affected by non-cardiac as well as
cardiopulmonary conditions.193,194
In selected cases, advanced cardiopulmonary exercise testing
(CPET) with spiro-ergometry may be performed. Reduced exercise
capacity is defined as a peak oxygen consumption (VO2 max)
<_20 mL/kg/min, and ventilatory inefficiency as a VE/VCO2 slope
>_30.166,195 Cardiopulmonary exercise testing provides objective evi-
dence of exercise capacity and may differentiate between cardiac and
non-cardiac causes (pulmonary, peripheral) for dyspnoea,157,166,196–200
but its value to distinguish between HFpEF and non-cardiac causes
may be limited.166 Cardiopulmonary exercise testing is not a typical
element in the initial HFpEF workup (see below).
If HFpEF is suspected after Step 1(P), a more specific assessment
may confirm or exclude the diagnosis (Step 2(E)).
Step 2(E): Echocardiographic and
natriuretic peptide heart failure with
preserved ejection fraction diagnostic
score
There is no single non-invasive diagnostic criterion for HFpEF so we
recommend a combination of echocardiographic measurements of
cardiac structure and function, and NP levels. Some may already be
available from Step 1(P).
Many of these measurements are continuously distributed within a
population, from normal to possibly abnormal and to overtly abnor-
mal values. Diagnostic cut-points may vary according to age, gender,
body weight, renal function, and the presence of atrial fibrillation.
Table 1 Risk factors and findings consistent with
heart failure with preserved ejection fraction in a
symptomatic patient






ECG abnormalities (beyond atrial fibrillation)
Elevated natriuretic peptide levels (if available, BNP >_ 35 pg/mL or
NT-proBNP >_ 125 pg/mL)











Table 2 Potential specific aetiologies underlying heart failure with preserved ejection fraction-like syndromes in
Step 4 (F2)
Abnormalities of the myocardium
lschaemic Myocardial post-infarction/scar49
Myocardial stunning50
Epicardial coronary artery disease51
Microvascular and endothelial dysfunction52,53–55
Toxic Recreational substance abuse Such as alcohol,56 cocaine,57 and anabolic steroids58
Heavy metals Such as iron,59 lead,60 cadmium,60 cobalt,61 copper (M. Wilson)62
Medications Such as chloroquine,63 ergotamine,64 cytostatic drugs (e.g. anthracy-
clines),64 immunomodulating drugs (e.g. interferons monoclonal
antibodies such as trastuzumab, cetuximab)64
Radiation Mean cardiac radiation doses > 3 Gy65,66
Immune and inflammatory Related to infection Such as cardiotropic viruses,67,68 HIV,69–71 hepatitis,72 helminths,73
parasites (e.g. Chagas’ disease74)
Not related to infection Lymphocytic myocarditis,75–79 autoimmune diseases (e.g. rheumatoid
arthritis,80 connective tissue disorders like scleroderma,81
M. Raynaud,55 systemic lupus erythematosus,82 dermato/polymyosi-
tis,83 and hypersensitivity and eosinophilic myocarditis73,84–87
Infiltrative Related to malignancy Direct infiltrations and metastases88–90
Not related to malignancy Amyloidosis,19,91 sarcoidosis,92,93 primarily and secondary haemo-
chromatosis,94–96 storage diseases97 (e.g. Fabry disease,98,99 Danon
disease,100–102 Pompe disease,99,102 PRKAG2 deficiency,99
Gaucher’s disease99)103,104,105,106
Metabolic Hormonal Such as thyroid diseases,107,108 parathyroid diseases,109 acromegaly,110
GH deficiency,111 Cushing disease,112 Conn’s disease,113 Addison
disease,114 phaeochromocytoma,115 pathologies related to preg-
nancy and peripartum116,117
Nutritional Such as deficiencies in thiamine,118 L-carnitine,119 selenium,120 (func-
tional) iron,121,122 complex malnutrition (e.g. AIDS, infections,73
anorexia nervosa73,123,124)
Genetic Diverse forms Such as HCM,97,125,126 restrictive cardiomyopathies,103,104,106 hyper-
trophic form of non-compaction cardiomyopathy,127,128 early forms of muscu-
lar dystrophies (Duchenne/Becker disease129).
Endomyocardial HES,84 EMF,71,127 endocardial fibroelastosis,128 carcinoid,130,131 endo-
cardial calcification (Paget’s disease132)
Abnormalities of loading conditions
Hypertension Primary and secondary forms of hypertension112,113,115,130,131
Valvular and structural defects Acquired Heart valve diseases133,134
Valvular and structural defects Congenital Septal defects132,135,136
Pericardial and endomyocardial pathologies Pericardial Constrictive pericarditis and pericardial effusion137,138
Endomyocardial HES,86 EMF,73,139 endocardial fibroelastosis,140 carcinoid,141,142 endo-
cardial calcification (Paget’s disease143)
High output states Severe anaemia,144 sepsis,145 thyrotoxicosis,105 arteriovenous fis-
tula,146 and pregnancy147
Volume overload Renal failure and fluid overload148,149,150
Abnormalities of the cardiac rhythm
Rhythm disorders Atrial/ventricular arrhythmias, pacing, conduction disorders38,151–153
EMF, endomyocardial fibrosis; GH, growth hormone; HCM, hypertrophic cardiomyopathy; HES, hypereosinophilic syndrome (formerly known as Löffler’s endocarditis); HIV/
AIDS, human immunodeficiency virus/acquired immune deficiency; LV, left ventricular; PRKAG2, protein kinase AMP-activated non-catalytic subunit gamma 2.





























































































To take account of these factors, we recommend the use of major
and minor diagnostic criteria according to the severity of an abnor-
mality and the presence of modifiers. Major criteria (and cut-points)
have been selected for their high specificity, while minor criteria
should be more sensitive. Cut-points were derived particularly from
studies that compared echocardiographic parameters against invasive
haemodynamic data.5,28,166
In one cohort with 64% prevalence of HFpEF determined by inva-
sive measurements, the univariable sensitivity of septal e0 velocity
<7 cm/s to diagnose HFpEF, without adjusting for age or other varia-
bles, was 46%, while its specificity was 76%.5 The sensitivity and speci-
ficity of an E/e0 ratio >9 were 78% and 59%, compared with 46% and
86% for E/e0 >13. The sensitivity and specificity of LA volume index
>30 mL/m2 were about 70%. Measurements of LV mass had low sen-
sitivity (26%) for HFpEF but high specificity (86%) if LVH was present.
PAP >35 mmHg [derived from tricuspid regurgitation (TR) velocity]
was 46% sensitive and 86% specific for HFpEF,5 which makes it an im-
portant diagnostic criterion. The utility of GLS <16% was moderate
(sensitivity 62% and specificity 56%5).201
The utility of NP levels varies according to several factors including
cardiac rhythm. For NT-proBNP >275 pg/mL, a sensitivity of 59%
and a specificity of 77% were reported (accuracy 68%).5 Sensitivity
decreased to 46% while specificity increased to 85% if the cut-off was
increased to >450 pg/mL (accuracy 66%). At our lowest recom-
mended cut-off of 125 pg/mL (minor criterion, if the patient is in sinus
rhythm), the sensitivity reported in that study was 77% and the speci-
ficity 53% (accuracy 65%). Of note, 39% of patients in that study
were in AF or had a history of paroxysmal AF.5 Combining the results
of E/e0 and NT-proBNP can increase their predictive value, notably
their sensitivity to diagnose HFpEF.202
Echocardiographic measurements of function and
morphology
In Step 1(P) we recommend standard echocardiography, at least to
assess LVEF and LV diameter. In Step 2(E) we recommend more
detailed echocardiographic measurements (Supplementary material
online, S1). These could all be obtained during a single study. The
echocardiographic criteria in the HFA–PEFF score, listed below, mir-
ror consensus recommendations for the diagnosis of LV diastolic
function.41
Septal and lateral mitral annular peak early diastolic velocity (e0)
Major criterion: septal e0<7 cm=s; or lateral e0<10 cm=s
½subjects aged <75 years
Major criterion: septal e0<5 cm=s; or lateral e0<7 cm=s
½subjects aged >_75 years
The main determinant of e0, the early diastolic velocity of mitral annu-
lar motion, is LV relaxation. It reflects LV lengthening and is influ-
enced by preload.203,204 Left ventricular longitudinal e0 velocity
declines with age;205 normative ranges reported from elderly partici-
pants were found to be lower than those given in the 2007 HFA con-
sensus.206 We include age-specific e0 criteria in the HFA–PEFF score,
measured as recommended.41
Average septal-lateral E/e0 ratio
Major criterion: average septal–lateral E=e0 ratio >_15
Minor criterion: average septal–lateral E=e0 ratio 9 -14
The ratio of the peak velocity of mitral inflow during early diastole
(E), recorded by pulsed Doppler between the tips of the mitral leaf-
lets, over the average of septal and lateral mitral annular early diastol-
ic peak velocities (e0) recorded by pulsed tissue Doppler, reflects the
mPCWP.41 The mitral E/e0 index correlates with LV stiffness and fi-
brosis20,21 and is less age-dependent than e0.206 It also has diagnostic
value during exercise.28,158 The E/e0 index is little influenced by
changes in volume but it is influenced by the severity of LVH.23,24
Tricuspid regurgitation peak velocity or
pulmonary arterial systolic pressure
Major criterion: TR peak velocity >2:8 m=s
Major criterion: Pulmonary artery systolic pressure >35 mmHg
Pulmonary arterial systolic pressure is calculated from the modified
Bernoulli equation as 4 peak TR velocity plus estimated right atrial
pressure. Elevated PASP and reduced RV function are important pre-
dictors of mortality in HFpEF.207–211 Even a moderate increase in
PASP can lead to increased ventricular interaction since a leftward
shift of the ventricular septum impedes LV filling.212 A PASP
>35 mmHg discriminates HFpEF from hypertensives and controls.207
A TR peak velocity >2.8 m/s indicates increased PASP41,213 and is an
indirect marker of LV diastolic dysfunction.41
Left ventricular global longitudinal
systolic strain
Minor criterion: GLS < 16%
Left ventricular peak systolic GLS is not angle-dependent, unlike
myocardial velocities recorded by tissue Doppler.186 It is measured
using speckle-tracking echocardiography as the average of systolic
strain obtained from all LV segments in the apical 4-chamber, apical
2-chamber, and apical long-axis views.214
Reduced LV longitudinal systolic strain and LV early diastolic strain
rate have both been identified in HFpEF.19,215,216 Impaired GLS pre-
dicts HF hospitalization, cardiovascular death, or cardiac arrest.216,217
It correlates with invasive measurements of LV stiffness and with NP
levels.19,204,218 All strain values are dimensionless and are expressed
as percentages. For ease of use in these recommendations, we sug-
gest a cut-point of 16% in absolute values;219–222 and a value below
16% (e.g. 14%) is recommended as a minor criterion.
Left atrial volume index
Major criterion: >34 mL=m2½in sinus rhythm
Major criterion: >40 mL=m2½in atrial fibrillation
Minor criterion: 29-34 mL=m2½in sinus rhythm
Minor criterion: 34–40 mL=m2½in atrial fibrillation



























































































The maximal volume of the LA, measured at end-systole from bi-
plane or three-dimensional images and indexed to body surface area
[left atrial volume index (LAVI)] is an indirect correlate of LV filling
pressures.41 It is more accurate as a marker of chronic LA remodel-
ling than either LA area or diameter223–225 and it correlates with
other echocardiographic indices of LV diastolic function.226 A LAVI
of 29–34 mL/m2 is considered as a minor criterion since it represents
the upper limit in healthy subjects.227,228
In patients without AF or heart valve disease, LAVI >34 mL/m2 in-
dependently predicts death, heart failure, AF, and ischaemic
stroke.229–231 In patients with HFpEF and permanent AF, LAVI was
35% more enlarged than it was in HFpEF patients in SR.34 Patients
with permanent AF may have a large LAVI even if they have no LV
diastolic dysfunction.34,41 We therefore recommend separate cut-
offs for LAVI in SR vs. AF.
Left ventricular mass index and relative
wall thickness
Major criterion: LVMI >_149 g=m2 in men or >_122 g=m2
in women and RWT >0:42
Minor criterion: LVMI >_115 g=m2 in men or >_95 g=m2 in women
or RWT >0:42 or LV end-diastolic wall thickness >_12 mm
Increased LV diastolic wall thickness in a non-dilated heart implies
that the patient has LVH. It develops first in the basal segments of the
ventricular septum,232 and a wall thickness >_12 mm at that site is
common in elderly people. Localized septal hypertrophy may be a
consequence of abnormal ventricular–arterial coupling but it is not
sufficient to indicate that there is significant global LV remodelling or
hypertrophy.
Left ventricular geometry is often classified using relative wall
thickness (RWT), calculated as twice the LV posterior wall thickness
divided by the LV internal diameter at end-diastole (LVPW  2/
LVIDD), and using left ventricular mass index (LVMI) normalized to
body surface area or height. Four patterns are described: normal
(normal LVMI, RWT <_0.42), concentric remodelling (normal LVMI,
RWT >0.42), concentric hypertrophy (increased LVMI, RWT
>0.42), and eccentric hypertrophy (increased LVMI, RWT
<_0.42).41,233,234 In patients with HFpEF, both concentric LVH and
concentric remodelling can be observed.235
The absence of LVH on echocardiography does not exclude
HFpEF.5 We therefore recommend the finding of concentric hyper-
trophy (increased LVMI and increased RWT) as a major criterion, or
any one of a lesser degree of LVH, RWT, and LV end-diastolic wall
thickness as a minor criterion.227,234,236
Natriuretic peptides
Major criterion: NT-proBNP >220 pg=mL;
or BNP >80 pg=mL ½in sinus rhythm
Major criterion: NT-proBNP >660 pg=mL or
BNP >240 pg=mL ½in atrial fibrillation
Minor criterion: NT-proBNP 125–220 pg=mL; or
BNP 35–80 pg=mL ½in sinus rhythm
Minor criterion: NT-proBNP 375–660 pg=mL; or
BNP 105–240 pg=mL ½in atrial fibrillation
In Step 1(P), a single low cut-point was recommended in order to
have a sensitive marker for cardiac abnormalities. In this step, in order
to increase specificity, a higher cut-off value is recommended as a
major criterion, in agreement with ESC guidelines.3 Cut-offs are also
stratified for the presence of SR or AF.
Natriuretic peptide levels should always be interpreted in con-
text.180 Definitive cut-offs to diagnose HFpEF in patients with SR or
in AF are not well established, and trials have used different val-
ues.237,238 In the setting of screening, average NPs have been
reported to be 3–3.5 fold higher in patients with AF than in patients
in SR.239 Average NPs were found to be threefold higher in patients
with AF than in patients in SR.34,35,240 In prevalent symptomatic
HFpEF with AF, levels tend to be even higher.241 For diagnosing
HFpEF, we hence recommend values in patients with AF that are
three times higher than used for patients in SR.
Calculating and interpreting the
HFA–PEFF score
The score has functional, morphological, and biomarker domains.
Within each domain, a major criterion scores 2 points or a minor cri-
terion 1 point (Figure 3; Supplementary material online, Table S1).
Each domain can contribute maximally 2 points, if any major criterion
from this domain is positive, or 1 point if no major but any minor cri-
terion is positive. If several major criteria within a single domain are
positive, this domain still contributes 2 points; and if no major but sev-
eral minor criteria are positive the contribution still is 1 point. Major
and minor criteria are not additive in a single domain. Points are
added only when they come from different domains.
For example, 2 major (E/e0 >15, and TR >2.8 m/s) and 1 minor
(GLS <16) criteria, all in the functional domain, will lead to a total
score from that domain of 2 points. The total score would be 5, if at
least one minor criterion (LAVI <34 mL/m2; LV wall thickness
>12 mm) and one major criterion (BNP in SR >80 pg/mL) would be
present coming from the morphological and biomarker domains, re-
spectively. It is important to understand that not all parameters from
each domain need to be recordable (which is typically the case). The
HFA-PEFF score can be calculated even if not all parameters are
obtained, which adds to the practical utility of the score.
A total score >_5 points is considered to be diagnostic of HFpEF,
while a score of <_1 point is considered to make a diagnosis of HFpEF
very unlikely and to mandate investigations for alternative causes.
Patients with an intermediate score (2–4 points, Figures 2 and 3) need
further evaluation (Step 3(F1); Figures 4A,B).
If LAVI, LVMI, or wall thickness cannot be assessed by echocardi-
ography, we recommend using measurements obtained from CMR
imaging instead. Of note, there are some systematic differences in
measurements of LV volumes and LVEF between imaging



















































..modalities.242 In one comparative study, LV volumes were larger and
LVEF was lower but not statistically different with CMR compared
with other imaging modalities.243
Step 3 (F1): Functional testing
Symptoms compatible with HF can be confirmed to originate from
the heart if haemodynamic abnormalities such as reduced stroke vol-
ume, reduced CO, and elevated LV filling pressures are detected ei-
ther at rest or during exercise. In a typical elderly patient with
multiple comorbidities, the presence or absence of isolated cardiac
structural and/or functional abnormalities at rest does not always es-
tablish or exclude the diagnosis of HFpEF. If invasive testing demon-
strates a high LV filling pressure [left ventricular end-diastolic
pressure (LVEDP) >_16 mmHg, PCWP >_15 mmHg] at rest, then the
diagnosis may be confirmed; otherwise, assessment during exercise is
recommended, either by non-invasive exercise stress echocardiog-
raphy or by invasive haemodynamics (Figures 2 and 4A,B).
Exercise stress echocardiography: the diastolic stress test
During exercise in healthy people, enhanced LV untwisting and early
diastolic suction maintain or increase stroke volume despite shorten-
ing of the filling time and without increasing LV filling pressures. In
patients with HFpEF, impaired early diastolic relaxation, reduced
increments in suction, and poor LV compliance lead to inadequate
increases in stroke volume and CO on exercise, increased LV filling
pressures, and increased PASP.28,41,244–248 High LV filling pressures
and inadequate CO responses during exercise can also impair RV
reserve.52
Many patients with HFpEF have symptoms mainly on exertion that
are usually attributed to the increase in LV filling pressures which is
needed to maintain adequate filling and stroke volume.159,249
Acquiring echocardiographic data during exercise can unmask LV dia-
stolic and systolic dysfunction. The parameters that have been
studied most often, during or immediately after exercise, are the mi-
tral E/e0 ratio and the TR peak velocity, which indicate increases in
mPCWP and PASP, respectively.28,41,244–248,250
Ideally a semi-supine bicycle test with imaging during exercise, or
else a treadmill or upright bicycle exercise protocol with imaging
at or immediately after peak stress, is recommended41,244 but
there are no universally adopted protocols. The European
Association of Cardiovascular Imaging and the American Society of
Echocardiography recommend a stepped protocol, starting at
25 W at 60 r.p.m. with the load increasing by 25 W every 3 min
until the patient has reached his maximal predicted workload and/
or maximal predicted heart rate (220—age in years) and/or devel-
oped limiting symptoms.244 Some patients cannot perform that
protocol, and a ramped exercise test on a semi-supine bicycle at
60 r.p.m. starting at 15 W and with increments of 5 W every mi-
nute has also been proposed, to a submaximal target heart rate of
100–110/min or until the patient develops limiting symptoms.245
None of these protocols have been shown to be superior to
others.
The mitral E/e0 ratio and peak TR velocity should be acquired at
baseline, during each stage including peak exercise, and during a
submaximal stage before fusion of the mitral E and A velocities213
or during the first 2 min of the recovery phase when mitral E and A
velocities are no longer fused and LV filling pressures remain
Figure 3 Step 2 (E): Echocardiographic and natriuretic peptide heart failure with preserved ejection fraction workup and scoring system (diagnos-
tic workup).


































elevated.41,244 Changes in CO can be assessed by measuring
the velocity integral of flow in the LV outflow tract, multiplied
by the HR.
Exercise echocardiography should be considered abnormal if
average E/e0 ratio at peak stress increases to >_15, with or without
a peak TR velocity >3.4 m/s.28,41,244 An increase only in TR velocity
should not be used to diagnose HFpEF because it might be caused
simply by a normal hyperdynamic response to exercise (with
increased pulmonary blood flow) in the absence of LV diastolic
dysfunction.251
An average E/e0 ratio during exercise >_15 adds 2 points to the
HFA–PEFF score. An average E/e0 ratio >_15 with a peak TR velocity
>3.4 m/s adds 3 points to the previous score from Step 2(E). If the
combined score from Step 2(E) and Step 3(F1) is >_5 points, then the
diagnosis of HFpEF can be confirmed.
However, echocardiographic stress tests also have limitations. It
was reported that E/e0 was not measurable in about 10% of subjects
during submaximal exercise (20 W) and in about 20% of HFpEF
patients during peak exercise, and that TR velocity was measurable in
only 50%; about 20% of controls were considered to have false-posi-
tive tests.28 Data from stress echocardiography are not sufficient to
substitute for invasive haemodynamic data under all circumstances. If
the score remains <5 points or if exercise echocardiography cannot
be performed, we recommend an invasive haemodynamic stress test
in any case of doubt, especially if a therapeutic decision depends on
the results.
Invasive haemodynamic tests at rest and with exercise
Left ventricular end-diastolic pressure LVEDP in the resting supine
position is typically obtained in the context of left heart catheteriza-
tion and bears important diagnostic information in the workup of un-
explained dyspnoea. In selected patients, LV compliance and stiffness
can be determined directly by using a multiple-loop conductance
Figure 4 Step 3 (F): Functional tests in cases of diagnostic uncertainty. (A, upper panel) It shows the diastolic stress test workup with exercise
echocardiography is shown. If key haemodynamic abnormalities are identified, a definite heart failure with preserved ejection fraction diagnosis can
be made. (B, lower panel) It shows the invasive haemodynamic measurements at rest (left) or during exercise (right) that may complement stress
echocardiography and are recommended in cases with remaining diagnostic uncertainty.































































































catheter to record the end-diastolic pressure–volume relationship
(EDPVR) during preload reduction, giving a volume-independent par-
ameter for LV stiffness (constant of chamber stiffness, b, normal
<0.27252).21,159,253–255 Invasive demonstration of impaired LV relax-
ation at rest, measured by high-fidelity pressure catheters as the time
constant of LV relaxation (tau, s > 48 ms4) or of elevated LV filling
pressures at rest (LVEDP >_16 mmHg) confirms definite evidence of
HFpEF.
Right heart catheterization should be considered for the struc-
tured workup of suspected HFpEF, especially when left heart pres-
sures are not available. When resting mPCWP, measured using a
Swan-Ganz catheter, is elevated in the presence of a normal LV end-
diastolic volume index, then usually LV end-diastolic distensibility is
reduced. A resting mPCWP >_15 mmHg3 confirms definite evidence
of HFpEF.
However, normal LVEDP or mPCWP levels at rest do not exclude
HFpEF. In compensated HFpEF, haemodynamic alterations may be
detected only during exercise or when the patient deterio-
rates.28,179,230,256,257 Also, volume depletion or intensified diuretic
treatment may shift the diastolic pressure–volume relationship to the
left, without changing LV compliance (dV/dP; the inverse of LV stiff-
ness252) If resting filling pressures are normal, exercise right heart
catheterization is recommended for the definite workup of unex-
plained exertional dyspnoea,179 especially if the patient has an inter-
mediate Score in Step 2(E) or if exercise echocardiography is
inconclusive or not feasible (Figures 2 and 4B). Specialized centres
may perform exercise right heart catheterization upfront in the ab-
sence of exercise echocardiography, depending on the individual ex-
perience of the site.
During supine exercise in healthy control subjects, cut-offs for
peak PCWP and LVEDP are <20–23 mmHg258,259 and <25
mmHg,260,261 respectively. Patients with values <25 mmHg during
peak exercise are classified as having non-cardiac dyspnoea. A
steep increase in PCWP during exercise is a typical haemodynamic
response in HFpEF,256,262 indicating that the dyspnoea on exertion
is mainly of cardiac origin. Patients with peak exercise PCWP
>_25 mmHg are classified as having HFpEF (Supplementary material
online, S2). An increase in LV filling pressure during exercise that is
not accompanied by increases in end-diastolic volume, indicates
limitation to LV filling or the development of pericardial
constraint.256
A high resting mPCWP and a pathological increase in mPCWP
during exercise predict poor outcomes from HFpEF.168,249,263
Patients with a normal mPCWP at rest (<12 mmHg) but a steep in-
crease during exercise (to >_25 mmHg) have a two-fold increase in
mortality.263 Ten-year mortality was 6.6% if resting mPCWP was
<_12 mmHg and peak exercise mPCWP was <25 mmHg; 28.2% in
patients with low mPCWP at rest and high exercise mPCWP; and
35.2% in those with high resting mPCWP and high peak exercise
mPCWP (>_25 mmHg).263
Exercise mPCWP reclassifies patients with a normal resting
mPCWP and stratifies risk. If other investigations have been inconclu-
sive, invasive measurement of mPCWP or LVEDP is considered as
the clinical reference investigation for diagnosing HFpEF28 (see
Supplementary material online, S7 about how to perform an invasive
stress test). Other causes such as significant CAD, mitral stenosis, or
pericardial constriction must be excluded.
Step 4(F2): Final aetiology
Most cases of HFpEF are related to common risk factors and comor-
bidities, but the possibility of a specific underlying aetiology should al-
ways be considered (Table 2, Supplementary material online, Tables
S2–S4; Figure 5A,B). We postulate that identification of specific HFpEF
aetiologies will advance the field of targeted therapies.
Specific heart muscle diseases that may present with
the HFpEF phenotype include hypertrophic cardiomyopa-
thies,125,264–266 myocarditis and chronic inflammatory cardiomyop-
athy,67,75–77,97,137,267,268 autoimmune diseases,78,79 non-infiltrative
and infiltrative cardiomyopathies,83,125 idiopathic or acquired endo-
myocardial fibrosis,269 storage diseases,125,269 and other genetic dis-
orders including early stages of cardiomyopathies associated with
muscular dystrophy.103 Rare causes such as toxicity from drugs or
heavy metals, radiation, and metabolic causes related to hormonal or
nutritional disease, should also be considered (Table 2). The trigger
may occur long before the onset of symptoms. For instance
radiation-induced HFpEF develops after 10–15 years, even when low
mean cardiac radiation doses of 3.3 Gy are used.104,129
Aetiological workup may include a standard exercise stress test
that may identify myocardial ischaemia, an abnormal blood pressure
response to exercise, chronotropic incompetence, or supraventricu-
lar and ventricular arrhythmias (Figure 5A; Supplementary material
online, S2). These findings can immediately translate into manage-
ment strategies, such as anti-ischaemic therapy, improved blood
pressure control, removal of bradycardic agents (such as beta-
blockers often prescribed for hypertension), and control of exercise-
induced cardiac arrhythmias.
More sophisticated tools for aetiological workup include CMR
which is most accurate for determining LA and LV volumes and
mass,270 detects scar and myocardial ischaemia due to epicardial cor-
onary disease or microvascular dysfunction,65 and stress perfusion
imaging to reveal diffuse subendocardial defects. Regional and diffuse
myocardial oedema (T2-imaging) and infiltration or fibrosis are quan-
tified using late gadolinium enhancement [LGE; for extracellular vol-
ume fraction (ECV)] or T1-mapping137,267,271–274 (Supplementary
material online, Table S3). Right or left ventricular myocardial biopsy,
(99m)Tc-DPD scintigraphy to identify cardiac amyloidosis, positron
emission tomography (PET)-CT, as well as specific genetic and la-
boratory tests (Figure 5B) should be considered in selected cases
where a specific aetiology is suspected.
Of note, we do not intend to lump together all causes of the clinic-
al syndrome of heart failure with a normal ejection fraction under the
term ‘HFpEF’, but instead to stress the importance to always consider
specific aetiologies if the clinical diagnosis of HFpEF is made. It is also
important to understand that non-myocardial aetiologies (Table 2)
that may mimic HFpEF, such as constrictive pericarditis, primary
valvular heart disease, or high output failure should not be considered
part of the HFpEF syndrome.
Limitations, gaps in evidence, and
unanswered questions
Heart failure with preserved ejection fraction is a clinical syndrome
with multiple contributing factors, aetiologies, and pathophysiological
expressions.168,275 It is a limitation that we suggest an algorithm that
reduces it to a single clinical diagnosis. Future studies should evaluate








































..and refine the recommended diagnostic algorithm and classify HFpEF
patients into specific subgroups. Ideally, a large and unselected sample
of breathless patients, and age-matched controls, would undergo all
tests including echocardiography and the ‘gold standard’ invasive
haemodynamic assessment.
The stage and severity of HFpEF may impact on the accuracy of a
specific diagnostic parameter. In a recent trial 45% of patients had
‘early’ HFpEF with normal filling pressures at rest, and elevated filling
pressures only during invasive haemodynamic exercise testing.5
Because of the intermittent diastolic pressure overload in early
HFpEF, LAVI may be smaller (and less diagnostic), and functional indi-
ces such as global LA strain or LA conduit strain might be more ap-
propriate diagnostic parameters.276 In consequence, the patient mix
under investigation may affect the test results. Prospective testing
and retesting in distinct HFpEF patients populations is needed to sort
this out.
The diagnosis of HF is still based on LVEF, partly for historical rea-
sons and despite its limitations277 for predicting cardiac functional re-
serve and symptoms. Exercise capacity correlates better with long-
axis functional reserve of the LV52,278–281 and with peripheral blood
flow282 than with LVEF. In fact, a preserved LVEF has no diagnostic
role for HFpEF except to exclude HF with reduced LVEF. In future,
real-time non-invasive assessments of chamber volumes, stroke vol-
umes, and CO, as well as filling pressures, in combination with in-
novative markers of systolic and diastolic function, will markedly
reduce the significance of LVEF in characterizing HF.
We have recommended exercise testing as a component of the
diagnostic workflow in cases of uncertainty, but there is no consensus
yet about which stress protocol should be used or which measure-
ments are most important. It is uncertain if a simple parameter such
as the 6MWT distance could be as useful as detailed cardiopulmon-
ary stress testing, which can be difficult to perform in breathless eld-
erly subjects.193
Besides increases in filling pressures, HFpEF patients may be
haemodynamically limited by their inability to adequately enhance
stroke volume during exercise,165,278,279,283 but no cut-points
have been published to diagnose the resulting impaired reserve of
CO. Unfortunately, reliable data on LV diastolic properties,
stroke volume, and CO can currently only be obtained invasively,
ideally by conductance catheterization. 3D echocardiography
and CMR is now reaching a state where pressure–volume loops
and stroke volumes can be obtained non-invasively,20,284 but
these measurements still await validation in broader HFpEF
cohorts.
Figure 5 Step 4 (F2): Final aetiological workup. (A) It shows the role of ergometry to detect underlying causes such as inadequate blood pressure
response, chronotropic incompetence, or myocardial ischaemia during exercise. (B) It shows the aetiological workup using cardiac magnetic reson-
ance (CMR). CT, computed tomography; PET, positron emission tomography.































































































It will be important not just to confirm the diagnosis using the scor-
ing system that we propose, but to document which specific abnor-
malities correlate with individual responses to treatment, in order to
dissect out specific pathophysiological mechanisms that need differ-
ent treatments.285,286 We recommend that future HFpEF studies and
registries should collect, record, and analyse the detailed compo-
nents that are included in the HF–PEFF Score.
There is a close relationship between HFpEF and AF. There is
overlap in symptoms, signs, echocardiographic findings, and NP levels
between the two conditions, and a substantial proportion of patients
in HFpEF registries and trials have AF. We have provided distinct
diagnostic thresholds for NP and LAVI in SR vs. AF, based on existing
literature and consensus. These thresholds need more prospective
research for their validation. In addition, other functional measures
are also likely to be affected by concomitant AF. Of note, we did not
adopt the alternative view that AF per se could be used as a stand-
alone indicator of HFpEF, but we again emphasize the close associ-
ation between AF and HFpEF.
There is controversy about the best non-invasive indicators of ele-
vated LV filling pressures and mPCWP.287 The E/e0 index has gained a
supremacy in clinical practice that is not fully supported by all clinical
investigations.288,289 The diagnostic utility of alternative indices such
as retrograde pulmonary venous flow,290,291 estimated LV stiffness
(diastolic pressure–volume quotient),284 and left atrial strain rate dur-
ing atrial contraction74,161,276,292 in patients in sinus rhythm, and the L
wave of mitral inflow293 and left atrial strain during reservoir func-
tion160,294 in patients in AF, merit further investigation.
Modern imaging methods generate a huge quantity of digital data
about global and regional left ventricular morphology and function
throughout the cardiac cycle, and about arterial and endothelial func-
tion and myocardial perfusion, which can be coupled with compre-
hensive demographic data including traditional risk factors and new
biomarkers and with proteomic, metabolomic, and genomic data.
Making sense of all this information is a challenge that can likely be
met by machine learning. Recent studies suggest that it may be useful
for diagnosis and for defining pathophysiology,15,295,296 but long-term
studies in large populations are needed to unravel which features
best predict clinical outcomes and responses to treatment.
Molecular phenotyping for a better identification of distinct HFpEF
phenotypes is emerging and may also help to develop targeted
therapies.
Supplementary material
Supplementary material is available at European Heart Journal online.
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